Clinical Trials Logo

Neuroendocrine Prostate Cancer clinical trials

View clinical trials related to Neuroendocrine Prostate Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05413421 Recruiting - Clinical trials for Metastatic Prostate Cancer

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer.

NCT ID: NCT04702737 Active, not recruiting - Clinical trials for Neuroendocrine Prostate Cancer

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

DeLLpro-300
Start date: June 10, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

NCT ID: NCT02709889 Terminated - Glioblastoma Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Start date: September 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

NCT ID: NCT01799278 Completed - Clinical trials for Neuroendocrine Prostate Cancer

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Start date: February 2013
Phase: Phase 2
Study type: Interventional

This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC). MLN8237 is an orally administered Aurora kinase A inhibitor that has demonstrated broad antitumor activity in vitro and in vivo. In preclinical models, aurora kinase inhibition resulted in dramatic and preferential anti-tumor activity in NEPC with suppression of neuroendocrine marker expression.